180 related articles for article (PubMed ID: 34784011)
1. Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan.
Hiraishi I; Ueno R; Watanabe A; Maekawa S
Clin Drug Investig; 2021 Dec; 41(12):1075-1086. PubMed ID: 34784011
[TBL] [Abstract][Full Text] [Related]
2. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38935253
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Qiu Y; Zhang Y; Teng M; Cheng S; Du Q; Yang L; Wang Q; Wang T; Wang Y; Dong Y; Dong H
Transplantation; 2024 Apr; 108(4):1021-1032. PubMed ID: 38049935
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.
Chan TS; Cheng SS; Chen WT; Hsu DC; Chau RW; Kang SH; Alsumali A; Kwong YL
J Med Econ; 2020 Dec; 23(12):1485-1492. PubMed ID: 33155494
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Groll AH; Schulte JH; Antmen AB; Fraser CJ; Teal VL; Haber B; Caro L; McCrea JB; Fancourt C; Patel M; Menzel K; Badshah C
Pediatr Infect Dis J; 2024 Mar; 43(3):203-208. PubMed ID: 38241643
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
[TBL] [Abstract][Full Text] [Related]
8. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
9. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
Kachur E; Roshdy D; Hamadeh I; Dodd B; Shahid Z
Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
11. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
12. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
13. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
14. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
15. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
16. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
17. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
19. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
